GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Jubilant Pharmova Ltd

Jubilant Pharmova Board Approves Rs. 800 Crore NCD Issuance

FUNDRAISE ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 12 Oct 2026, 12:35 PM IST  ·  BSE ID: fa3c490f-5c45-425d-98d0-04e0f61288f6
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board agreed to borrow up to ₹800 crore by selling new debt instruments called NCDs to investors.
🤖 AI Summary
  • Jubilant Pharmova board approved issuance of up to ₹800 crore NCDs via private placement.
  • NCDs will be secured/unsecured, listed, rated, redeemable, and transferable.
  • Company seeking member approval for total debt securities issuance up to ₹2,500 crore.
  • NCDs will have a face value of ₹1,00,000 each and tenure up to five years.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Aggregate amount of NCDs
up to ₹800 crore
Face value of NCD
₹1,00,000
Aggregate amount of debt securities for member approval
not exceeding ₹2,500 crore
Tenure of NCD
Upto five years from the Deemed Date of Allotment
🏢 How This Affects the Company
📈
Business Impact
This issuance provides an avenue for the company to raise capital for its operational and strategic needs.
💰
Financial Impact
The NCD issuance will increase the company's debt obligations and interest expenses but provides working capital.
⚠️
Risk Impact
The company's leverage will increase due to the secured/unsecured debt issuance.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders regarding this NCD issuance.
👤
Who Is Affected
This directly affects debenture holders upon issuance and indirectly affects equity shareholders through the company's capital structure changes.
🔍
Management Signal
Management is demonstrating proactive capital raising to fund ongoing and future operations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Completion of member approval via postal ballot for debt issuance.
Details of the bidding process for NCD issuance.
Record date for the postal ballot and subsequent shareholder meeting.
MEDIUM RISK Significant debt issuance up to ₹2,500 crore increases financial leverage and interest burden.
💡 Investor Takeaway
Jubilant Pharmova approved up to ₹800 crore NCD issuance via private placement. Seeking member approval for ₹2,500 crore debt securities up to five-year tenure.
⚖️ Strengths & Concerns

✅ Positives

  • Board approval for issuance of up to ₹800 crore Non-Convertible Debentures provides funding flexibility.
  • NCDs are proposed to be listed on BSE, offering potential liquidity for investors.

⚠️ Concerns

  • Seeking member approval for a total debt securities issuance not exceeding ₹2,500 crore indicates significant future borrowing.
  • The coupon/interest rate is to be discovered during the bidding process, creating uncertainty in financing cost.
❓ Frequently Asked Questions
What is the total amount Jubilant Pharmova plans to issue in Non-Convertible Debentures?
The company's board has approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore.
What is the face value of each Non-Convertible Debenture issued by Jubilant Pharmova?
Each Non-Convertible Debenture (NCD) has a face value of ₹1,00,000.
What is the maximum aggregate amount of debt securities Jubilant Pharmova is seeking member authorization for?
The company is seeking members' authorization for an aggregate amount not exceeding ₹2,500 crore for debt securities.
What is the proposed tenure for the Non-Convertible Debentures (NCDs)?
The Non-Convertible Debentures (NCDs) will have a tenure of up to five years from the Deemed Date of Allotment.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.